Loading...

Top
Help
×

By creating an account you can:

Logo TaxTMI
Call Us / Help / Feedback

Contact Us At :

E-mail: [email protected]

Call / WhatsApp at: +91 99117 96707

For more information, Check Contact Us

FAQs :

To know Frequently Asked Questions, Check FAQs

Most Asked Video Tutorials :

For more tutorials, Check Video Tutorials

Submit Feedback/Suggestion :

Email :
Please provide your email address so we can follow up on your feedback.
Category :
Description :
Min 15 characters 0/2000
Make Most of Text Search
  1. Checkout this video tutorial: How to search effectively on TaxTMI.
  2. Put words in double quotes for exact word search, eg: "income tax"
  3. Avoid noise words such as : 'and, of, the, a'
  4. Sort by Relevance to get the most relevant document.
  5. Press Enter to add multiple terms/multiple phrases, and then click on Search to Search.
  6. Text Search
  7. The system will try to fetch results that contains ALL your words.
  8. Once you add keywords, you'll see a new 'Search In' filter that makes your results even more precise.
  9. Text Search
Add to...
You have not created any category. Kindly create one to bookmark this item!
Create New Category
Hide
Title :
Description :
❮❮ Hide
Default View
Expand ❯❯
Close ✕
🔎 News - Adv. Search
TEXT SEARCH:

Press 'Enter' to add multiple search terms. Rules for Better Search

Search In:
Main Text + AI Text
  • Main Text
  • Main Text + AI Text
  • AI Text
Category: ?
Categorized by AI
---- All Categories ----
  • ---- All Categories ----
  • Income Tax
  • GST
  • Customs, DGFT & SEZ
  • FEMA & RBI
  • Corp. Laws, SEBI & IBC
  • PMLA, Black Money & ED
  • Budget
  • News and Press Release
  • PTI News
Month:
---- All Months ----
  • ---- All Months ----
  • January
  • February
  • March
  • April
  • May
  • June
  • July
  • August
  • September
  • October
  • November
  • December
Year:
---- All Years ----
  • ---- All Years ----
  • 2026
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
Sort By: ?
In Sort By 'Default', exact matches for text search are shown at the top, followed by the remaining results in their regular order.
Relevance Default Date
❯❯
Maximize Maximize Maximize
0 / 200
Expand Note
Add to Folder

No Folders have been created

+

Are you sure you want to delete "My most important" ?

NOTE:

News
Showing Results for :
Reset Filters
Results Found:
Show All Summaries Hide All Summaries
April 4, 2026
Show AI Summary
Digital audit report requirements govern electoral trusts claiming exclusion of voluntary contributions from total income.
FN 181 is a mandatory digital audit report for an electoral trust seeking exclusion of reported voluntary contributions from total income. It must be prepared by an accountant, filed electronically with the Commissioner of Income Tax (CPC) through the e-filing portal, and submitted on or before the due date for filing the return of income. The form cannot be filed offline or edited after submission, and a valid PAN is mandatory for filing.
April 4, 2026
Show AI Summary
Employee welfare fund approval under income tax rules depends on notified purposes, verified disclosure, and hearing before rejection.
Form 180 is the electronic application for approval or renewal of an employee welfare fund established for notified purposes under section 11(3) read with Schedule VII, to be filed by the trust or fund before the jurisdictional PCIT/CIT and verified by the trustee or principal officer. The form requires details of the trust or fund, employer organisation, objects, trustees, employee membership, contributions, income, application or accumulation of funds, along with the trust deed, activity notes and accounts. Approval is granted only if the prescribed conditions are satisfied, for a period not exceeding three tax years, and rejection requires recorded reasons and an opportunity of hearing.
April 4, 2026
Show AI Summary
Employee Welfare Fund approval through Form 180 requires online filing, valid PAN, and strict trust-based eligibility conditions.
Form 180 is the prescribed electronic application for an Employee Welfare Fund seeking approval or renewal from the jurisdictional Principal CIT/CIT. The fund must be a trust for notified welfare purposes for serving employees or their dependents, and the application must be verified by the trustee or principal officer. Filing is mandatory for approval, which confers pass-through treatment and tax exemption subject to conditions. The form can be filed only online, cannot be edited after submission, and requires a valid PAN and supporting documents.
April 4, 2026
Show AI Summary
Business connection in India compliance through Form 173 for eligible investment funds and annual verification of eligibility conditions.
Form 173 is a statement furnished by an eligible investment fund to verify compliance with the conditions for claiming that its activities do not constitute a business connection in India. The form is filed once in a tax year within 90 days from the end of the tax year, and it contains particulars on residence, tax identification number, Schedule I compliance, participation interests in India, fund manager remuneration, and investment profits. Supporting documents may include approval orders, registrations, financial statements, and remuneration contracts.
April 4, 2026
Show AI Summary
Eligible investment fund reporting under no-business-connection rules requires mandatory online Form 173 filing and digital signature compliance.
Form 173 is the mandatory statement for an eligible investment fund to establish that its activities do not create a business connection in India. It must be filed once in a tax year, within 90 days from the end of the tax year, by the fund manager or designated person, only through the Income Tax e-filing portal, and it cannot be edited after submission. The form requires supporting fund details, registrations, financial statements, and digital signature compliance, and a valid PAN is mandatory.
April 4, 2026
Show AI Summary
Eligible investment fund reporting under Form 172 requires accountant certification, electronic filing, and compliance with prescribed conditions.
Form 172 is the accountant's report for an eligible investment fund to establish fulfilment of prescribed conditions relevant to section 9(12) and the claim that the fund's activities do not create a business connection in India. It is prescribed under Rule 274(7), filed once in each tax year by the appointed accountant, and due by 31 October of the succeeding tax year. The form is filed electronically with a UDIN and digital signature, and non-filing may attract penalty under section 447.
April 4, 2026
Show AI Summary
Business connection in India reporting through Form 172 requires mandatory electronic filing, UDIN generation, and supporting documentation.
Form 172 is the mandatory accountant's report for an eligible investment fund to show compliance with conditions for claiming no business connection in India. It is filed once in a tax year by the appointed accountant through the Income Tax e-filing portal, after UDIN generation and digital signature. The form requires a valid PAN, cannot be edited after submission, and may need supporting documents such as fund manager details, SEBI registrations, financial statements, and contracts relating to the fund manager's activities and remuneration.
April 3, 2026
Show AI Summary
Authorised Income Tax Practitioner registration under Form 171 depends on eligibility, supporting documents, and authority verification.
Form 171 is the one-time application for registration as an authorised Income Tax Practitioner under the specified eligibility categories in section 515(3) of the Income Tax Act, 2025. Eligible applicants include accountants, persons who have passed a recognised accountancy examination, and other qualified persons recognised by the Central Board of Direct Taxes. The form requires applicant details, the claimed eligibility category, qualifications, prior tax appearances, and supporting documents, and is filed with the jurisdictional Income Tax Authority for verification and registration.
April 3, 2026
Show AI Summary
Authorised Income-tax Practitioner registration through Form 171 requires eligibility details, supporting documents, and one-time filing.
Form 171 is the prescribed application for registration as an Authorised Income-tax Practitioner under section 515 of the Income-tax Act 2025 and must be filed with the jurisdictional Chief Commissioner or Commissioner of Income-tax. The application is mandatory for recognition in that capacity, may be filed after eligibility arises, and is a one-time filing unless otherwise directed. It requires applicant particulars, eligibility details, qualifications, supporting documents, and relevant firm or association details. On approval, the applicant's name is entered in the Register of Income-tax Practitioners and a Certificate of Registration is issued.
April 3, 2026
Show AI Summary
Annual Information Statement consolidates tax credits, payments, transactions, and proceedings in a taxpayer's e-filing account.
Form 168 operates as an auto-generated Annual Information Statement linked to a taxpayer's PAN and available in the e-filing account. It consolidates TDS, TCS, tax payments, specified financial transactions, demand and refund details, and pending or completed proceedings, together with any other prescribed information. The taxpayer does not file the form manually. It is updated dynamically during the year as underlying reports and payments are processed, and it uses Tax Year instead of Financial Year.
April 3, 2026
Show AI Summary
Annual Information Statement and taxpayer summary streamline income reporting through detailed verification, feedback correction, and consolidated return filing.
Annual Information Statement (AIS) is the detailed financial statement linked to PAN, and Taxpayer Information Summary (TIS) is its consolidated version showing category-wise totals for use in return filing. AIS contains transaction-level data, while TIS provides summarized figures such as salary, rental income, interest, capital gains, dividend, business income and taxes paid. Taxpayers should verify AIS, use the feedback mechanism for incorrect or unrelated entries, and rely on the updated TIS; actual income must still be reported in the return even if missing from AIS.
April 3, 2026
Show AI Summary
GST appeal filing blocked by NIL demand entries despite unpaid dispute over liability and prior voluntary payment.
Taxpayers may face portal restrictions when an adjudication order reflects a NIL demand because payment was made at the show cause notice stage without admitting liability. Although such payment does not amount to acceptance of the demand, the GST portal may block filing of appeal application APL-01 when no liability is captured in the Demand and Collection Register. The taxpayer may seek rectification of the order so that the correct demand amount is reflected and the appeal can then be filed within the prescribed time.
April 3, 2026
Show AI Summary
Annual reporting for film production and specified activities under the income-tax framework now requires structured disclosure and TDS linkage.
Form 164 requires persons engaged in cinematograph film production or notified specified activities to furnish an annual statement for each tax year under section 507 of the Income-tax Act, 2025, read with Rule 236. The statement is due within 60 days from the end of the tax year and covers filer particulars, film or activity details, and payment and TDS information, including aggregate payments above the prescribed threshold linked to the relevant film or activity. The revised format uses three parts and standardised digital reporting.
April 3, 2026
Show AI Summary
Mandatory annual statement for film production and specified activities covers incomplete projects, threshold payments, TAN, and electronic filing status.
A mandatory annual statement is required under section 507 of the Income-tax Act, 2025 for persons engaged in cinematograph film production or specified activities such as event management, sports events, documentary production, OTT or TV programme production, performing arts, or similar notified activities. The filing obligation applies to every individual, partnership firm, LLP, company or other entity that produced a film or undertook a specified activity during the relevant tax year, including cases where the film or activity was not completed in that year. The statement must be filed within 60 days from the end of the tax year, and TAN is required where the filer is liable to deduct tax at source.
April 3, 2026
Show AI Summary
Personal loan flexibility expands as longer repayment tenure, collateral-free borrowing, and faster disbursal aim to ease EMI burden.
Bajaj Finance has revised its personal loan offering by extending the repayment tenure up to 108 months, replacing the earlier 96-month structure. The longer tenure is intended to reduce monthly EMI burden and give borrowers greater flexibility in managing repayments, while shorter tenures remain available within a range of 12 months to 108 months depending on customer preference. The personal loan product is described as collateral-free and designed for planned and urgent expenses, with loan amounts ranging from Rs. 40,000 to Rs. 55 lakh.
April 3, 2026
Show AI Summary
Indirect transfer reporting under Form 163 requires timely electronic disclosure of share transfers affecting Indian assets and control rights.
Form 163 is the reporting statement for indirect transfers of assets located in India under section 506 of the Income-tax Act, 2025 and Rule 235 of the Income-tax Rules, 2026. It is to be furnished by an Indian concern, or its representative, where a non-resident transfers shares or interests in a foreign company or entity in a manner affecting assets, rights, management or control in relation to the Indian concern. The form is filed electronically within the prescribed timelines and supports computation of income reported in Form 4.
April 3, 2026
Show AI Summary
Foreign exchange reserves decline as rupee pressure, RBI dollar sales, and lower gold and currency assets shape weekly movement.
India's foreign exchange reserves declined to USD 688.058 billion for the week ended March 27, driven by lower foreign currency assets and gold reserves. The Reserve Bank of India continued to intervene in the foreign exchange market through dollar sales and related policy measures as the rupee remained under pressure, while Special Drawing Rights rose slightly and the IMF reserve position edged down.
April 3, 2026
Show AI Summary
Indirect transfer reporting in Form No. 163 requires timely electronic filing, supporting documents, and a valid PAN.
Reporting of indirect transfers of assets located in India requires an Indian concern, or its representative, to furnish information in Form No. 163 under section 506 of the Income Tax Act, 2025. The form is mandatory and applies where a non-resident transfers shares of, or interest in, an offshore company or entity resulting in an indirect transfer of assets in India. It must be furnished within ninety days from the end of the financial year, or within ninety days of the transaction where management or control rights in relation to the Indian concern are transferred.
April 3, 2026
Show AI Summary
Annual statement filing for liaison offices in India requires RBI-linked disclosure, electronic submission, and timely compliance.
Form 162 is an annual statement required under section 505 of the Income Tax Act, 2025, for non-resident entities maintaining a liaison office in India. It must be filed once in each tax year within eight months from the end of the tax year, electronically through the income-tax e-filing portal and digitally signed by the authorised signatory. The form captures head office, liaison office, RBI approval, Annual Activity Certificate, financial, employee, and counterparty details, and may be used for verification, international taxation, and transfer pricing cross-checks.
April 3, 2026
Show AI Summary
Annual statement compliance for liaison offices requires electronic filing, certified activity records, valid PAN, and timely submission.
Form 162 is the annual statement required for non-resident entities maintaining a liaison office in India under the Income-tax Act, 2025, to be filed electronically once in each tax year within eight months from the end of the tax year. The filing requires particulars relating to the office's activities, approval details, employees, Indian counterparties, and audited financial information, along with a certified Annual Activity Certificate and valid PAN. The form cannot be submitted offline or edited after acknowledgment, and non-filing or delay may attract penalty, revocation of liaison office permission, and other assessment-related action.

News

Back

All News

Showing Results for :
Reset Filters
No Records Found

News

Back

All News

Showing Results for : Reset Filters
Customs & Trade

Built on Service, Trust and Quality: How Alpex Pharma Became the Manufacturing Partner Pharma Brands Rely On

March 19, 2026

Contents
Summary
Note

Note

-

Bookmark

Print

Print

With a multi-certified, multi-division manufacturing infrastructure and an established presence across domestic and international markets, Alpex Pharma is setting a new benchmark for what third-party pharmaceutical manufacturing should look like in India. INDIA — The Indian pharmaceutical industry stands at a defining moment. Domestic demand is surging, regulatory standards are tightening, and Indian-made medicines are earning growing respect in markets across Asia, Africa, and beyond. At the centre of this transformation is a quiet but powerful engine — the contract manufacturer. And few have positioned themselves for this moment as deliberately, or as decisively, as Alpex Pharma. Under the leadership of Director Shubham Mittal, Alpex Pharma has built a manufacturing organisation that bears none of the hallmarks of a conventional contract facility. It operates with the systems, the certifications, the infrastructure, and the service philosophy of an enterprise that was designed from the outset to support pharma brands at scale — domestically and globally. A Manufacturing Organisation Built for Regulated Markets At the foundation of Alpex Pharma’s operations is a quality infrastructure that meets and exceeds the standards of the world’s most demanding pharmaceutical regulatory frameworks. The company holds WHO-GMP, GMP, GLP, and Ghana-GMP certifications — the gold standard combination for manufacturers supplying both India’s domestic market and regulated international markets. The addition of Ghana-GMP accreditation signals something beyond compliance. It reflects a strategic commitment to international manufacturing standards and demonstrates that Alpex Pharma’s quality systems have been independently verified against the requirements of export-destination regulators — not just domestic ones. For brand partners with global ambitions, this distinction matters enormously. Global Reach Through Strategic Partnerships Alpex Pharma enables pharma brands to access international markets through established neutral code manufacturing partnerships — producing under partner brand identities across multiple geographies. This infrastructure allows brand owners to expand globally without the capital investment of building their own international supply chain. Specialist Divisions. Enterprise-Grade Separation. One of the clearest indicators of a manufacturer’s true capability is not its equipment list — it is how it organises itself. Alpex Pharma operates across three dedicated, fully separated manufacturing divisions, each purpose-built for its product category with the infrastructure, containment protocols, and compliance architecture it demands. • General Division : Tablets, capsules across a broad therapeutic range, serving domestic and export markets with full GMP compliance. • Beta-Lactam Division : Dedicated Beta-Lactam manufacturing with full containment, regulatory separation and specialist protocols for sensitive antibiotic classes. • Cephalosporin Division : Isolated Cephalosporin production infrastructure meeting the highest standards of cross-contamination prevention and regulatory compliance. This level of divisional separation is not common among Indian contract manufacturers. It reflects an investment in doing things properly — the kind of structural commitment that enterprise pharma clients, institutional buyers, and international regulators look for when evaluating a manufacturing partner for the long term. “Quality is not a stage in our production process. It is the architecture of eveAlpexng we build — every division, every system, every client relationship.” — Shubham Mittal, Director, Alpex Pharma The Standard That Sets Alpex Pharma Apart What distinguishes Alpex Pharma in a crowded contract manufacturing landscape is not any single certification or facility specification. It is the consistent experience of every brand that works with the company — an experience defined by reliability, transparency, and a service culture that treats each client’s business as seriously as its own. Alpex Pharma’s account management model is built on dedicated partnerships. Brand owners are not passed between teams or managed through a generic helpdesk. They work with a dedicated team that understands their product portfolio, their market, their regulatory requirements, and their commercial timelines — and is accountable for all of it. Production scheduling is built around the client’s launch windows and distribution cycles. And delivery commitments, once made, are treated as non-negotiable. This is the operational definition of service, trust and quality — not as corporate values on a wall, but as the daily practice of a manufacturing organisation that has built its entire reputation on them. It is also precisely why Alpex Pharma has become the top third-party manufacturer of choice for pharma brands across India and international markets. “We do not want to be the largest manufacturer in the room. We want to be the most trusteAlpex PharmaIndia’s that every brand in our portfolio would recommend without hesitation.” — Shubham Mittal, Director, Alpex Pharma India’s Pharma Ambition Needs Partners Like This India’s contract manufacturing sector is undergoing a generational shift. The brands emerging from this market are more sophisticated, more globally ambitious, and more discerning about their supply chain partners than any previous generation. They are not looking for the cheapest option. They are looking for the most reliable one — a manufacturing partner whose quality systems, international credentials, service culture, and operational discipline can match their own ambitions and protect their brand as they grow. Alpex Pharma has positioned itself squarely in that space. Not as a commodity contract manufacturer competing on price, but as a quality-led enterprise competing on performance. With internationally recognised certifications, enterprise-grade divisional infrastructure, established global export pathways, and a service philosophy rooted in genuine partnership, the company represents a new standard for what third-party pharmaceutical manufacturing can and should be in India. The pharmaceutical brands that choose Alpex Pharma are not simply outsourcing production. They are gaining a manufacturing partner with the capability, the credentials, and the commitment to grow with them — wherever that growth takes them. About Alpex Pharma Alpex Pharma is a leading third-party pharmaceutical manufacturer based in India, holding WHO-GMP, GMP, GLP, and Ghana-GMP certifications. Operating across three specialist divisions — General, Beta-Lactam, and Cephalosporin — the company serves pharma brands in domestic and international markets with a commitment to quality, reliability, and partnership. For more information, visit www.alpexpharma.in. Media Contact Alpex Pharma — Communications Email: [email protected] Website: www.alpexpharma.in (Disclaimer: The above press release comes to you under an arrangement with NRDPL and PTI takes no editorial responsibility for the same.). PTI PWR

Topics

Acts Income Tax